DelveInsight’s Myofascial Pain Syndrome Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Myofascial Pain Syndrome Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Myofascial Pain Syndrome Market report covers emerging drugs, current treatment practices, market share of the individual therapies, and the current forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best opportunities and assess the underlying potential of the market.
Myofascial Pain Syndrome: An Overview
Myofascial pain syndrome (MPS) is characterized by regional pain originating from hyperirritable spots located within taut bands of skeletal muscle, known as myofascial trigger points (MTrPs). Common etiologies of myofascial pain and dysfunction may be from direct or indirect trauma, spine pathology, exposure to cumulative and repetitive strain, postural dysfunction, and physical deconditioning.
Get access to a free copy of our latest sample report @ https://www.delveinsight.com/sample-request/myofascial-pain-syndrome-market
Some of the key highlights of the Myofascial Pain Syndrome Market Report
- As per the article by Urits et al. (2020), titled “Treatment and Management of Myofascial Pain Syndrome”, patients with myofascial pain represent a large portion of the patient population, and the prevalence of TrPs among patients presenting to medical clinics due to widespread pain ranges from 30-93%.
- As per MSD Manuals, Myofascial pain syndrome (MPS) is the most common disorder affecting the temporomandibular region. It is more common among women and has a bimodal age distribution in the early 20s and around menopause.
- According to Southwest Orofacial Group, Myofascial trigger points are more likely to be active in women than in men, with 55% of women having latent trigger points, compared to 45% in men.
Myofascial Pain Syndrome Market
The Myofascial Pain Syndrome market size is anticipated to increase during the study period owing to the increasing incident population and rising awareness of the Myofascial Pain Syndrome Market in the 7MM. The expected launch of emerging therapies and the research and development activities of pharmaceutical companies will also fuel the market growth during the forecast period.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Myofascial Pain Syndrome Market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Myofascial Pain Syndrome Market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Download Free Sample Report @ https://www.delveinsight.com/sample-request/myofascial-pain-syndrome-market
Myofascial Pain Syndrome Epidemiology
The epidemiology section covers insights into the historical and current Myofascial Pain Syndrome Market patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Myofascial Pain Syndrome Market Drugs & Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Myofascial Pain Syndrome Market or expected to get launched in the market during the study period. The analysis covers Myofascial Pain Syndrome market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Myofascial Pain Syndrome Market Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies. Unmet needs in the Myofascial Pain Syndrome include therapies that are oral, anthracycline sparing and deliverable in resource-limited settings. Another major unmet need is the relapse and refractory cases in the patients given treatment with Doxil.
Browse More Related Reports @ https://www.delveinsight.com/sample-request/myofascial-pain-syndrome-market
Myofascial Pain Syndrome Treatment Market
Pharmacologic treatment of Myofascial Pain includes Nonsteroidal anti-inflammatory drugs (NSAIDs), Cyclooxygenase-2 (COX-2) inhibitors, Tropisetron, Opioids, lidocaine patch, Tizanidine, Tricyclic antidepressants (TCAs), Botulinum type A toxin (BoNT-A) and many others while Non-pharmacologic Treatment of Myofascial Pain include Injections into MTrPs, Dry needling, Manual therapy and others.
Myofascial Pain Syndrome Market Insights
The current market is driven by off-label therapies and with limited investment by the key industry players for the treatment of MPS, the emerging market is not expected to shift drastically.
Myofascial Pain Syndrome Market Dynamics
There is currently no approved dug for the treatment of MPS, so the physicians generally prescribe off label therapies such as topical anesthetic treatment which includes lidocaine, tetracaine, diclofenac sodium, and thiocolchicoside applied either as a cream or as a patch, nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2 (COX-2) inhibitors, tropisetron, opioids, tizanidine, tricyclic antidepressants, botulinum type a toxin, and many others.
Discover more information about the report @ https://www.delveinsight.com/sample-request/myofascial-pain-syndrome-market
Table of content
- Key Insights
- Executive Summary
- Competitive Intelligence Analysis
- Market Overview at a Glance
- Disease Background and Overview
- Patient Journey
- Epidemiology and Patient Population
- Treatment Algorithm, Current Treatment, and Medical Practices
- Unmet Needs
- Key Endpoints of Myofascial Pain Syndrome Market Treatment
- Marketed Products
- Emerging Therapies
- Seven Major Market Analysis
- Attribute analysis
- 7MM: Market Outlook
- Access and Reimbursement Overview
- KOL Views
- Market Drivers
- Market Barriers
- Appendix
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/